Cargando…

Pharmacokinetics of maropitant citrate in Rhode Island Red chickens (Gallus gallus domesticus) following subcutaneous administration

Maropitant citrate is a synthetic neurokinin‐1 receptor antagonist and substance P inhibitor used for control of emesis in dogs in cats. Maropitant citrate is used empirically in birds, despite a lack of pharmacokinetic data in avian species. The objective of this study was to determine the pharmaco...

Descripción completa

Detalles Bibliográficos
Autores principales: Mones, Alissa B., Petritz, Olivia A., Knych, Heather K., Sadar, Miranda J., Thomson, Andrea E., Guzman, David Sanchez‐Migallon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544110/
https://www.ncbi.nlm.nih.gov/pubmed/35734891
http://dx.doi.org/10.1111/jvp.13082
_version_ 1784804526654488576
author Mones, Alissa B.
Petritz, Olivia A.
Knych, Heather K.
Sadar, Miranda J.
Thomson, Andrea E.
Guzman, David Sanchez‐Migallon
author_facet Mones, Alissa B.
Petritz, Olivia A.
Knych, Heather K.
Sadar, Miranda J.
Thomson, Andrea E.
Guzman, David Sanchez‐Migallon
author_sort Mones, Alissa B.
collection PubMed
description Maropitant citrate is a synthetic neurokinin‐1 receptor antagonist and substance P inhibitor used for control of emesis in dogs in cats. Maropitant citrate is used empirically in birds, despite a lack of pharmacokinetic data in avian species. The objective of this study was to determine the pharmacokinetic profile of a single dose of maropitant citrate 1 and 2 mg/kg subcutaneously (SC) in eight Rhode Island Red hens (Gallus gallus domesticus). A crossover study design was used with 1‐week washout between trials. Blood samples were collected over 36 h after drug administration. Plasma concentrations were measured using liquid chromatography–tandem mass spectrometry and pharmacokinetic parameters were determined via non‐compartmental analysis. The mean maximum plasma concentration, time to maximum concentration, and elimination half‐life following 1 and 2 mg/kg SC were 915.6 ± 312.8 ng/ml and 1195.2 ± 320.2 ng/ml, 0.49 ± 0.21 h and 1.6 ± 2.6 h, and 8.47 ± 2.24 h and 8.58 ± 2.6 h, respectively. Pharmacokinetic data suggests doses of 1 or 2 mg/kg SC may be administered every 12–24 h to maintain above target plasma concentration similar to dogs (90 ng/ml). These data provide a basis for further investigation of maropitant citrate pharmacokinetics and pharmacodynamics in birds.
format Online
Article
Text
id pubmed-9544110
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95441102022-10-14 Pharmacokinetics of maropitant citrate in Rhode Island Red chickens (Gallus gallus domesticus) following subcutaneous administration Mones, Alissa B. Petritz, Olivia A. Knych, Heather K. Sadar, Miranda J. Thomson, Andrea E. Guzman, David Sanchez‐Migallon J Vet Pharmacol Ther Original Articles Maropitant citrate is a synthetic neurokinin‐1 receptor antagonist and substance P inhibitor used for control of emesis in dogs in cats. Maropitant citrate is used empirically in birds, despite a lack of pharmacokinetic data in avian species. The objective of this study was to determine the pharmacokinetic profile of a single dose of maropitant citrate 1 and 2 mg/kg subcutaneously (SC) in eight Rhode Island Red hens (Gallus gallus domesticus). A crossover study design was used with 1‐week washout between trials. Blood samples were collected over 36 h after drug administration. Plasma concentrations were measured using liquid chromatography–tandem mass spectrometry and pharmacokinetic parameters were determined via non‐compartmental analysis. The mean maximum plasma concentration, time to maximum concentration, and elimination half‐life following 1 and 2 mg/kg SC were 915.6 ± 312.8 ng/ml and 1195.2 ± 320.2 ng/ml, 0.49 ± 0.21 h and 1.6 ± 2.6 h, and 8.47 ± 2.24 h and 8.58 ± 2.6 h, respectively. Pharmacokinetic data suggests doses of 1 or 2 mg/kg SC may be administered every 12–24 h to maintain above target plasma concentration similar to dogs (90 ng/ml). These data provide a basis for further investigation of maropitant citrate pharmacokinetics and pharmacodynamics in birds. John Wiley and Sons Inc. 2022-06-23 2022-09 /pmc/articles/PMC9544110/ /pubmed/35734891 http://dx.doi.org/10.1111/jvp.13082 Text en © 2022 The Authors. Journal of Veterinary Pharmacology and Therapeutics published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Mones, Alissa B.
Petritz, Olivia A.
Knych, Heather K.
Sadar, Miranda J.
Thomson, Andrea E.
Guzman, David Sanchez‐Migallon
Pharmacokinetics of maropitant citrate in Rhode Island Red chickens (Gallus gallus domesticus) following subcutaneous administration
title Pharmacokinetics of maropitant citrate in Rhode Island Red chickens (Gallus gallus domesticus) following subcutaneous administration
title_full Pharmacokinetics of maropitant citrate in Rhode Island Red chickens (Gallus gallus domesticus) following subcutaneous administration
title_fullStr Pharmacokinetics of maropitant citrate in Rhode Island Red chickens (Gallus gallus domesticus) following subcutaneous administration
title_full_unstemmed Pharmacokinetics of maropitant citrate in Rhode Island Red chickens (Gallus gallus domesticus) following subcutaneous administration
title_short Pharmacokinetics of maropitant citrate in Rhode Island Red chickens (Gallus gallus domesticus) following subcutaneous administration
title_sort pharmacokinetics of maropitant citrate in rhode island red chickens (gallus gallus domesticus) following subcutaneous administration
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544110/
https://www.ncbi.nlm.nih.gov/pubmed/35734891
http://dx.doi.org/10.1111/jvp.13082
work_keys_str_mv AT monesalissab pharmacokineticsofmaropitantcitrateinrhodeislandredchickensgallusgallusdomesticusfollowingsubcutaneousadministration
AT petritzoliviaa pharmacokineticsofmaropitantcitrateinrhodeislandredchickensgallusgallusdomesticusfollowingsubcutaneousadministration
AT knychheatherk pharmacokineticsofmaropitantcitrateinrhodeislandredchickensgallusgallusdomesticusfollowingsubcutaneousadministration
AT sadarmirandaj pharmacokineticsofmaropitantcitrateinrhodeislandredchickensgallusgallusdomesticusfollowingsubcutaneousadministration
AT thomsonandreae pharmacokineticsofmaropitantcitrateinrhodeislandredchickensgallusgallusdomesticusfollowingsubcutaneousadministration
AT guzmandavidsanchezmigallon pharmacokineticsofmaropitantcitrateinrhodeislandredchickensgallusgallusdomesticusfollowingsubcutaneousadministration